Market research
ALTHX.PA Theranexus Société Anonyme
PA EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 61M
- P/E ratio
- Not available
- Analyst target
- 5.8
- Dividend yield
- Not available
- Beta
- 1.52
Profile
Company facts
- Exchange
- PA
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- FR0013286259
- Market cap
- 61M
- P/E ratio
- Not available
- Analyst target
- 5.8
- Dividend yield
- Not available
- Beta
- 1.52
About
About Theranexus Société Anonyme
THX Pharma Société Anonyme, a biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system disorders. It is involved in the development of Batten-1, an initial drug candidate currently under Phase ½ clinical study for rare neurological disease, as well as TX01 for the treatment of Gaucher disease and Niemann-Pick type C diseases. The company was formerly known as Theranexus Société Anonyme and change its name to THX Pharma Société Anonyme in September 2025. The company was founded in 2013 and is headquartered in Lyon, France.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the ALTHX.PA discussion.
5 years, 5 months ago
Theranexus Société Anonyme is currently in a long term downtrend where the price is trading 26.9% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Based on the above factors, Theranexus Société Anonyme gets an overall score of 1/5.